Citation Tools
PDF
Other content recommended for you
- Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I
- Effectiveness, safety and costs of orphan drugs: an evidence-based review
- Should rare diseases get special treatment?
- Criteria to define rare diseases and orphan drugs: a systematic review protocol
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- Time to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis
- Prehospital emergency care in a humanitarian environment: an overview of the ethical considerations
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
- Rare diseases, orphan drugs, and orphan diseases